{"filing":{"accession_number":"0001193125-26-314591","cik":"0001829802","ticker":"SNSE","company_name":"Faeth Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"d68855d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526314591/d68855d8k.htm"},"events":[{"id":20196,"run_id":18181,"accession_number":"0001193125-26-314591","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board approved one-time supplemental performance-based stock option grants to current employees including CEO Anand Parikh (398,018 options), General Counsel Christopher Gerry (84,766 options), and SVP Finance Josiah Craver (30,824 options) under the 2026 Equity Incentive Plan. This is a compensatory arrangement for named executives and officers, with vesting contingent on achieving a $70.00 stock price hurdle over a four-year performance period. The disclosure of equity grants to senior management constitutes a material executive compensation event.","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19496,"accession_number":"0001193125-26-314591","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved one-time supplemental performance-based stock option grants to current employees including CEO Anand Parikh (398,018 options), General Counsel Christopher Gerry (84,766 options), and SVP Finance Josiah Craver (30,824 options) under the 2026 Equity Incentive Plan. This is a compensatory arrangement for named executives and officers, with vesting contingent on achieving a $70.00 stock price hurdle over a four-year performance period. The disclosure of equity grants to senior management constitutes a material executive compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T21:16:40.555230+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19496,"accession_number":"0001193125-26-314591","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved one-time supplemental performance-based stock option grants to current employees including CEO Anand Parikh (398,018 options), General Counsel Christopher Gerry (84,766 options), and SVP Finance Josiah Craver (30,824 options) under the 2026 Equity Incentive Plan. This is a compensatory arrangement for named executives and officers, with vesting contingent on achieving a $70.00 stock price hurdle over a four-year performance period. The disclosure of equity grants to senior management constitutes a material executive compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T21:16:40.555230+00:00","company_name":"Faeth Therapeutics, Inc.","ticker":"SNSE","filing_date":"2026-07-23"}]}